Cardiol Therapeutics
CRDL
35 hedge funds and large institutions have $11.7M invested in Cardiol Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
95% more capital invested
Capital invested by funds: $6.02M → $11.7M (+$5.73M)
9% more funds holding
Funds holding: 32 → 35 (+3)
0.56% less ownership
Funds ownership: 10.62% → 10.07% (-0.56%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
+$711K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$151K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$81.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$61.6K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$58.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AXS Investments
Port Chester,
New York
|
-$579K |
| 2 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$522K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$73.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$55.5K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$23.8K |
CRDL Hedge Fund Activity: Q1 2024 in Review
35 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q1 2024, worth a combined $11.7M — up 95% from $6.02M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CRDL positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Tejara Capital, adding an estimated $711K. The largest seller was AXS Investments, exiting entirely with an estimated $579K sold.
- 35 institutional investors held Cardiol Therapeutics (CRDL) as of Q1 2024, up from 32 in Q4 2023.
- Funds reported $11.7M of Cardiol Therapeutics stock for Q1 2024, up 95% quarter-over-quarter.
- 6 funds opened new Cardiol Therapeutics positions in Q1 2024 and 3 closed out, a net change of +3 holders.
- The largest Cardiol Therapeutics buyer in Q1 2024 was Tejara Capital, an estimated $711K added.
- The largest Cardiol Therapeutics seller in Q1 2024 was AXS Investments, an estimated $579K sold.
Based on aggregated 13F filings for Q1 2024.